Replies to post #722013 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

“It’s nearly seven years after that first CAR-T approval and [capacity to meet demand] is still an issue,” said Touchon.

Indeed, five more of these custom-made CAR T-cell therapies have since reached market, in indications ranging from multiple myeloma — Johnson & Johnson’s/Legend Biotech’s Carvykti and Bristol Myers Squibb’s Abecma — to various types of lymphoma — Kite Gilead’s Yescarta and Tecartus as well as BMS’ Breyanzi — and ALL (Tecartus).

All face the capacity challenge in some way.”

https://www.mmm-online.com/home/channel/7-day-supply/car-t-makers-quest-to-scale-drugs-production/

[Investor082]

Do you sense a pattern with these posters? Pretty much everyone with FDA approved products are bad and NWBO is the best in class, LOL! ;)

That should make the bar for success really low with FDA applications and eventually approvals. I wonder why they haven’t applied to FDA, 4 years since data lock and counting.